News Image

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Provided By PR Newswire

Last update: Apr 30, 2025

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –

Read more at prnewswire.com

IMMUNIC INC

NASDAQ:IMUX (7/25/2025, 8:00:01 PM)

After market: 1.12 0 (0%)

1.12

+0.05 (+4.67%)



Find more stocks in the Stock Screener

Follow ChartMill for more